Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-338078
Filing Date
2026-08-06
Accepted
2026-08-06 16:18:02
Documents
47
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q janx-20260630.htm   iXBRL 10-Q 2667341
2 EX-31.1 janx-ex31_1.htm EX-31.1 18483
3 EX-32.1 janx-ex32_1.htm EX-32.1 10303
  Complete submission text file 0001193125-26-338078.txt   10218603

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20260630.xsd EX-101.SCH 1007125
50 EXTRACTED XBRL INSTANCE DOCUMENT janx-20260630_htm.xml XML 2203192
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40475 | Film No.: 261249382
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)